 |
| Date | Title | | | 12/19/11 | Ardea Biosciences Initiates Phase 3 Clinical Development Program for Lesinurad| SAN DIEGO, CA, Dec 19, 2011 (MARKETWIRE via COMTEX) --Ardea Biosciences, Inc. (NASDAQ: RDEA) today announced that it has initiated the first of four planned Phase 3 clinical trials in its development program for lesinurad, the Company's lead product candidate for the chronic treatment of gout. The lesinurad Phase 3 development program is expected to involve approximately 2,000 gout patients at sites around the world. The remaining Phase 3 studies in the program are expected to begin shortly.
"... |
|  | | 11/15/11 | Ardea Biosciences to Present at Upcoming Investor Conferences| SAN DIEGO, CA, Nov 15, 2011 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) announced today that Barry D. Quart, PharmD, president and chief executive officer, will be presenting at the following upcoming investor conferences: -- Lazard Capital Markets 8th Annual Healthcare Conference in New York,
NY. Presentation at 3:00 p.m. EST on Wednesday, November 16, 2011.
-- Piper Jaffray 23rd Annual Healthcare Conference in New York, NY.
Presentation at 4:00 p.m. EST o... |
| | | 11/07/11 | Ardea Biosciences Provides Additional Positive Clinical Results for Lesinurad and Initial Clinical Results for RDEA3170 at the 2011 ACR/ARHP Annual Scientific Meeting| 90% Response Rate at 44 Weeks for Lesinurad/Allopurinol Combination in Ongoing Extension Period of Phase 2b Study
CHICAGO, IL, Nov 07, 2011 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA) announced that additional results from the ongoing extension period of a Phase 2b study (Study 203) of lesinurad, Ardea's lead product candidate for the chronic treatment of gout, in combination with allopurinol, are being presented today at the 2011 ACR/ARHP Annual Scientific Meeting in Chi... |
| | | 11/04/11 | Ardea Biosciences Reports Recent Accomplishments, Important Upcoming Events and Third Quarter 2011 Financial Results| SAN DIEGO, CA, Nov 04, 2011 (MARKETWIRE via COMTEX) -- Ardea Biosciences, Inc. (NASDAQ: RDEA), a biotechnology company focused on the development of small-molecule therapeutics for the treatment of serious diseases, today reported recent accomplishments and financial results for the three and nine months ended September 30, 2011.
"Since our last quarterly update, we have advanced our development program for lesinurad and continue to target commencing Phase 3 studies before the end of this ye... |
| |
|
|
| There are currently no events scheduled. |
Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. |
|
